KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Return on Capital Employed (2018 - 2026)

Aquestive Therapeutics has reported Return on Capital Employed over the past 8 years, most recently at 62.12% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 2668.0% year-over-year to 62.12%; the TTM value through Dec 2025 reached 62.12%, down 2668.0%, while the annual FY2025 figure was 85.28%, 3446.0% down from the prior year.
  • Return on Capital Employed for Q4 2025 was 62.12% at Aquestive Therapeutics, down from 54.14% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 13.85% in Q2 2024 and troughed at 281.76% in Q4 2022.
  • A 5-year average of 96.49% and a median of 76.76% in 2021 define the central range for Return on Capital Employed.
  • Biggest five-year swings in Return on Capital Employed: tumbled -19856bps in 2022 and later skyrocketed 24413bps in 2023.
  • Year by year, Return on Capital Employed stood at 83.2% in 2021, then plummeted by -239bps to 281.76% in 2022, then skyrocketed by 87bps to 37.64% in 2023, then rose by 6bps to 35.44% in 2024, then crashed by -75bps to 62.12% in 2025.
  • Business Quant data shows Return on Capital Employed for AQST at 62.12% in Q4 2025, 54.14% in Q3 2025, and 70.31% in Q2 2025.